. Author manuscript; available in PMC: 2018 Jun 1.

Published in final edited form as: Mol Cancer Res. 2017 Feb 14;15(6):765–775. doi: 10.1158/1541-7786.MCR-16-0183

Table 1. Mutational data and GI₅₀s for cell lines treated with PI3K inhibitors.

Cell line ER, PR, HER2/Neu/ERBB2 status, PIK3CA mutational status, PTEN mutational status, other documented mutations, and inhibitor GI₅₀s observed (pan PI3Ki: GDC-0941, PI3K-αi: BYL719, PI3K-βi: AZD6482). Abbreviations: pos = positive, neg = negative, wt = wild type, mut = mutation, del = deletion, amp = amplification, missense = missense mutation, TP53 = Tumor protein p53, CDKN2A = Cyclin-dependent kinase inhibitor 2A, HDM2 = Human double minute 2 homolog, RB1 = Retinoblastoma protein, Smad4 = Mothers against decapentaplegic homolog 4 and EGFR = Epidermal growth factor receptor.

Cell Line	ER	PR	HER2	PIK3CA	PTEN	Other Mutations	Pan PI3Ki GI₅₀ (μM)	PI3Kαi GI₅₀ (μM)	PI3Kβi GI₅₀ (μM)
IME/HMEC	pos	pos	neg	wt	wt	hTERT immortalized	1.41	4.90	>10
BT474	pos	pos	pos	K111N	wt	TP53 missense	0.09	0.30	3.31
MCF7	pos	pos	neg	E545K	wt	CDKN2A del, HDM2 amp	0.14	0.34	9.82
HCC70	neg	neg	neg	wt	nonsense mut		0.85	0.85	0.54
BT549	neg	neg	neg	wt	nonsense mut	RB1 del, TP53 missense	0.62	>10	>10
MDAMB468	neg	neg	neg	wt	nonsense mut	RB1 del, SMAD4 del, TP53 missense, EGFR amp	0.14	>10	0.10

Table 1. Mutational data and GI50s for cell lines treated with PI3K inhibitors.

Table 1. Mutational data and GI₅₀s for cell lines treated with PI3K inhibitors.